TCF21 and non-small cell lung carcinoma: In 2011, Richards et al. (71) concluded that TCF21 hypermethylation and impaired TCF21 expression are specific and frequent in NSCLC cells, even in early-stage disease, thereby making TCF21 a potential biomarker for early-stage NSCLC.